Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract Cancer
- First Posted Date
- 2006-09-26
- Last Posted Date
- 2009-11-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 84
- Registration Number
- NCT00380588
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan
Comparison of Two Approaches to Insulin Therapy in Patients With Type 2 Diabetes (IOOX)
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Insulin lispro mid mixture (MM)Drug: Insulin glargine
- First Posted Date
- 2006-09-19
- Last Posted Date
- 2009-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 484
- Registration Number
- NCT00377858
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Malaga, Spain
A Trial for Patients With Advanced/Recurrent Endometrial Cancer
- Conditions
- NeoplasmsNeoplasms by SiteUrogenital NeoplasmsGenital Neoplasms, FemaleUterine NeoplasmsEndometrial NeoplasmsCancer of EndometriumEndometrial CancerCancer of the EndometriumEndometrium Cancer
- Interventions
- First Posted Date
- 2006-09-18
- Last Posted Date
- 2009-11-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 27
- Registration Number
- NCT00377520
- Locations
- 🇺🇸
Gynecologic Oncology Group 215-854-0770, Philadelphia, Pennsylvania, United States
A Study in People With Mild Hypertension
- Conditions
- Mild Hypertension
- First Posted Date
- 2006-09-12
- Last Posted Date
- 2007-05-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 153
- Registration Number
- NCT00374855
- Locations
- 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Stockholm, Sweden
Pemetrexed Plus Cisplatin Bi-Weekly, in Patients With Urothelial Cancer (Metastatic, Locally Advanced or Non-Resectable)
- First Posted Date
- 2006-09-12
- Last Posted Date
- 2010-11-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 59
- Registration Number
- NCT00374868
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santander, Spain
Dosage Schedule Study of Pemetrexed Monochemotherapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2006-08-31
- Last Posted Date
- 2009-10-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 19
- Registration Number
- NCT00370292
- Locations
- 🇮🇹
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy
Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer
- Conditions
- Non-Small-Cell Lung Cancer
- Interventions
- Drug: LY573636-sodium
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2018-10-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 52
- Registration Number
- NCT00363766
- Locations
- 🇮🇹
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Sisto, Italy
Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2009-10-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 908
- Registration Number
- NCT00363415
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom
A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma
- Conditions
- Colorectal Carcinoma
- First Posted Date
- 2006-08-09
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 38
- Registration Number
- NCT00362102
Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting
- Conditions
- Coronary Artery Disease
- Interventions
- First Posted Date
- 2006-07-28
- Last Posted Date
- 2010-08-31
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 201
- Registration Number
- NCT00357968
- Locations
- 🇮🇱
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Hashomer, Israel